– DCC-3116 Shown to Inhibit EGFR and EGFR Family Inhibitor-induced Autophagy in Multiple EGFR-mutant Non-Small Cell Lung Cancer Cell Lines and Decrease Tumor Burden in Combination with Osimertinib and ...
DANVILLE, Va. (WDBJ) - Plans are lifting off to expand the Danville Regional Airport’s aviation training program. Right now, Averett University’s Aeronautics Program takes place at the airport. Soon, ...
Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer ...
– Treatment was Generally Well-Tolerated with Treatment-Emergent Adverse Events Mostly Grade 1 or 2 – – Based on Preliminary Results, the Expansion Cohorts for DCC-3014 in TGCT Patients Opened at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results